scorecardresearch
Add as a preferred source on Google
Thursday, February 5, 2026
TopicCorbevax

Topic: Corbevax

DCGI approval in, but here’s why you can’t choose Corbevax as your booster just yet

Corbevax was, over the weekend, approved for heterologous use as a Covid booster shot by apex drug regulator Drugs Controller General of India.

Drug authority clears Covaxin, Corbevax for children aged 5 to 12

DGCI also allowed emergency use of Zycov-D (Zydus Cadila vaccine) for children above 12 years.

Cleared Corbevax for ages 12-14 based on interim safety & immune response data, govt tells LS

Govt was responding to question on availability of safety & efficacy data for Corbevax, and whether it had been peer-reviewed. It sidestepped queries on efficacy & peer-review.

Corbevax is India’s ‘lowest priced vaccine’, saves exchequer Rs 1500 cr, Biological E says

Hyderabad-based Biological E has priced its vaccine at Rs 990 in the private market. For the government, however, the vaccine is at just Rs 145, making it very affordable.

DCGI gives emergency use approval to Biological E’s Corbevax vaccine for kids aged 12-18

It is the second Covid vaccine to get approval for use in children in India after Bharat Biotech's Covaxin.

5 months after nod, ZyCov-D set for rollout in 7 states. Bihar starts getting 1st set of shots

It will be used in six other states too. Corbevax of Biological E is also expected to start coming in this month. No decision so far on the government procuring Covovax.

Corbevax, a new patent-free Covid vaccine, is an important step to end pandemic

Corbevax was developed with global vaccine access in mind. The goal was to make a low-cost, easy-to-produce and -transport vaccine.

What it will take to vaccinate the world against Covid

A Q&A with vaccine scientist Peter Hotez, author of 'Preventing the Next Pandemic', on developing a low-cost Covid vaccine, and why Omicron won’t be the end of the pandemic.

Corbevax maker says ‘too much dependence on MNCs, focus on new tech’ behind vaccine inequity

Corbevax co-developer Dr Peter Hotez says the vaccine will 'make up for lost time' in race to immunise millions and its patent was waived in the spirit of 'decolonisation'.

How Corbevax and Covovax, the two vaccines newly approved in India, fight Covid

India granted emergency-use authorisation to two new Covid vaccines, Corbevax and Covovax, this week. Both use proteins of the coronavirus to induce an immune response.

On Camera

2026 defence budget is not good enough to achieve Viksit armed forces

The creation of Viksit armed forces requires a national security vision for 2047, a national security strategy reviewed every five years, and a national defence policy.

Tax increase shakes India’s $36 billion arbitrage trade

Arbitrage fund managers are bracing for lower returns after govt raised taxes on equity derivatives. Arbitrage funds gained traction in India last yr as foreign investors exited equities.

Trade deal sorted, India & US move on to pending defence pacts—P-8I aircraft first, engines next

Defence Acquisition Council likely to take up P-8I procurement, cleared in 2019, in third week this month. Proposed joint production of GE F414-INS6 engine also on agenda.

Swiss report should now close Op Sindoor debate. Knowing when to stop the fight is key too

The key to fighting a war successfully, or even launching it, is a clear objective. That’s an entirely political call. It isn’t emotional or purely military.